MannKind Corp (MNKD) - Net Assets
Based on the latest financial reports, MannKind Corp (MNKD) has net assets worth $-59.20 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($744.40 Million) and total liabilities ($803.60 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check MNKD tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-59.20 Million |
| % of Total Assets | -7.95% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 98.1 |
MannKind Corp - Net Assets Trend (2000–2025)
This chart illustrates how MannKind Corp's net assets have evolved over time, based on quarterly financial data. See MannKind Corp liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for MannKind Corp (2000–2025)
The table below shows the annual net assets of MannKind Corp from 2000 to 2025. For live valuation and market cap data, see market cap of MannKind Corp.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $-51.02 Million | +35.26% |
| 2024-12-31 | $-78.82 Million | +67.98% |
| 2023-12-31 | $-246.17 Million | +1.74% |
| 2022-12-31 | $-250.54 Million | -19.67% |
| 2021-12-31 | $-209.35 Million | -16.03% |
| 2020-12-31 | $-180.42 Million | +5.30% |
| 2019-12-31 | $-190.53 Million | -8.82% |
| 2018-12-31 | $-175.08 Million | +18.46% |
| 2017-12-31 | $-214.73 Million | -16.96% |
| 2016-12-31 | $-183.59 Million | +47.59% |
| 2015-12-31 | $-350.33 Million | -374.90% |
| 2014-12-31 | $-73.77 Million | -140.19% |
| 2013-12-31 | $-30.71 Million | +72.25% |
| 2012-12-31 | $-110.68 Million | +64.71% |
| 2011-12-31 | $-313.65 Million | -69.06% |
| 2010-12-31 | $-185.53 Million | -213.29% |
| 2009-12-31 | $-59.22 Million | -168.28% |
| 2008-12-31 | $86.73 Million | -76.18% |
| 2007-12-31 | $364.10 Million | -5.06% |
| 2006-12-31 | $383.49 Million | +85.28% |
| 2005-12-31 | $206.98 Million | +37.65% |
| 2004-12-31 | $150.36 Million | +34.76% |
| 2003-12-31 | $111.58 Million | +22.92% |
| 2002-12-31 | $90.77 Million | +184.64% |
| 2000-12-31 | $31.89 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to MannKind Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 314937400000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $3.08 Million | % |
| Other Comprehensive Income | $115.00K | % |
| Other Components | $3.14 Billion | % |
| Total Equity | $-51.02 Million | 100.00% |
MannKind Corp Competitors by Market Cap
The table below lists competitors of MannKind Corp ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
FARM FRESH BERHAD
KLSE:5306
|
$1.16 Billion |
|
Ambea AB
ST:AMBEA
|
$1.16 Billion |
|
Avia Avian PT Tbk
JK:AVIA
|
$1.16 Billion |
|
OVH GROUPE UNSP.ADR/1/2
F:7U70
|
$1.16 Billion |
|
Chongqing Gas Grp Corp Ltd
SHG:600917
|
$1.16 Billion |
|
Shenzhen Farben Information Technology Co.Ltd.
SHE:300925
|
$1.16 Billion |
|
Bombay Burmah Trading Corporation Limited
NSE:BBTC
|
$1.16 Billion |
|
Focus Technology Co Ltd
SHE:002315
|
$1.16 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in MannKind Corp's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -78,816,000 to -51,022,000, a change of 27,794,000.
- Net income of 5,863,000 contributed positively to equity growth.
- Other comprehensive income decreased equity by 994,000.
- Other factors increased equity by 22,925,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $5.86 Million | +11.49% |
| Other Comprehensive Income | $-994.00K | -1.95% |
| Other Changes | $22.93 Million | +44.93% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares MannKind Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2000-12-31 | $25.40 | $3.87 | x |
| 2002-12-31 | $33.69 | $3.87 | x |
| 2003-12-31 | $30.18 | $3.87 | x |
| 2004-12-31 | $29.81 | $3.87 | x |
| 2005-12-31 | $25.96 | $3.87 | x |
| 2006-12-31 | $37.62 | $3.87 | x |
| 2007-12-31 | $22.75 | $3.87 | x |
| 2008-12-31 | $4.27 | $3.87 | x |
| 2009-12-31 | $-2.78 | $3.87 | x |
| 2010-12-31 | $-8.16 | $3.87 | x |
| 2011-12-31 | $-12.87 | $3.87 | x |
| 2012-12-31 | $-3.06 | $3.87 | x |
| 2013-12-31 | $-0.51 | $3.87 | x |
| 2014-12-31 | $-0.96 | $3.87 | x |
| 2015-12-31 | $-4.31 | $3.87 | x |
| 2016-12-31 | $-1.99 | $3.87 | x |
| 2017-12-31 | $-2.06 | $3.87 | x |
| 2018-12-31 | $-1.21 | $3.87 | x |
| 2019-12-31 | $-0.97 | $3.87 | x |
| 2020-12-31 | $-0.81 | $3.87 | x |
| 2021-12-31 | $-0.84 | $3.87 | x |
| 2022-12-31 | $-0.97 | $3.87 | x |
| 2023-12-31 | $-0.92 | $3.87 | x |
| 2024-12-31 | $-0.28 | $3.87 | x |
| 2025-12-31 | $-0.16 | $3.87 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently MannKind Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 1.68%
- • Asset Turnover: 0.44x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-38.38%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2000 | -77.33% | -16013.64% | 0.00x | 1.34x | $-27.85 Million |
| 2002 | -227.23% | 0.00% | 0.00x | 1.15x | $-215.34 Million |
| 2003 | -59.04% | 0.00% | 0.00x | 1.13x | $-77.04 Million |
| 2004 | -50.54% | 0.00% | 0.00x | 1.09x | $-91.03 Million |
| 2005 | -55.24% | 0.00% | 0.00x | 1.10x | $-135.04 Million |
| 2006 | -60.12% | -230548.00% | 0.00x | 1.41x | $-268.90 Million |
| 2007 | -80.52% | -2931900.00% | 0.00x | 1.49x | $-329.60 Million |
| 2008 | -349.39% | -1515195.00% | 0.00x | 3.26x | $-311.71 Million |
| 2009 | 0.00% | 0.00% | 0.00x | 0.00x | $-214.18 Million |
| 2010 | 0.00% | -183397.85% | 0.00x | 0.00x | $-152.01 Million |
| 2011 | 0.00% | -321608.00% | 0.00x | 0.00x | $-129.44 Million |
| 2012 | 0.00% | -483902.86% | 0.00x | 0.00x | $-158.30 Million |
| 2013 | 0.00% | -6048.33% | 0.01x | 0.00x | $-188.42 Million |
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $-191.00 Million |
| 2015 | 0.00% | 0.00% | 0.00x | 0.00x | $-333.41 Million |
| 2016 | 0.00% | 71.91% | 1.63x | 0.00x | $144.02 Million |
| 2017 | 0.00% | -999.00% | 0.14x | 0.00x | $-95.86 Million |
| 2018 | 0.00% | -312.20% | 0.26x | 0.00x | $-69.47 Million |
| 2019 | 0.00% | -82.34% | 0.67x | 0.00x | $-32.85 Million |
| 2020 | 0.00% | -87.87% | 0.60x | 0.00x | $-39.20 Million |
| 2021 | 0.00% | -107.27% | 0.23x | 0.00x | $-59.99 Million |
| 2022 | 0.00% | -87.60% | 0.34x | 0.00x | $-62.35 Million |
| 2023 | 0.00% | -6.00% | 0.42x | 0.00x | $12.68 Million |
| 2024 | 0.00% | 9.66% | 0.72x | 0.00x | $35.47 Million |
| 2025 | 0.00% | 1.68% | 0.44x | 0.00x | $10.97 Million |
Industry Comparison
This section compares MannKind Corp's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $296,451,843
- Average return on equity (ROE) among peers: -36.17%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| MannKind Corp (MNKD) | $-59.20 Million | -77.33% | N/A | $1.16 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $81.00 Million |
| Abcellera Biologics Inc (ABCL) | $1.15 Billion | -12.70% | 0.29x | $1.55 Billion |
| Abeona Therapeutics Inc (ABEO) | $-17.08 Million | 0.00% | 0.00x | $321.39 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-18.59 Million | 0.00% | 0.00x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $-75.73 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $97.37 Million | -71.81% | 0.35x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $2.46 Million | -172.46% | 1.68x | $33.54 Million |
| Abivax SA American Depositary Shares (ABVX) | $455.01 Million | -73.87% | 0.28x | $7.77 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $1.23 Billion | 31.86% | 0.27x | $3.59 Billion |
About MannKind Corp
MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. It offers Afrezza inhalation powder, an inhaled insulin used to improve… Read more